P/E at 37.13 vs Industry's 34.62: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Market Confidence

The current P/E of 37.13 for Sun Pharmaceutical Industries Ltd stands approximately 7.3% above the industry average of 34.62. This premium suggests that investors are willing to pay a higher multiple for the company’s earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. Such a valuation often reflects expectations of superior earnings growth, stronger market positioning, or better operational efficiency. However, it also raises questions about whether the premium is justified given recent performance trends — what is the current rating?

Performance Across Timeframes: A Consistent Outperformer

Examining returns over multiple periods reveals a consistent pattern of outperformance by Sun Pharmaceutical Industries Ltd. Over one year, the stock gained 8.30%, while the Sensex declined by 7.30%. This positive alpha extends to shorter and longer horizons: the three-month return is 8.91% versus the Sensex’s -8.67%, and the year-to-date performance stands at 9.20% compared to the Sensex’s -11.25%. Even over five years, the stock has surged 172.04%, significantly outpacing the Sensex’s 49.66% gain. This strong relative performance underscores the company’s resilience amid broader market volatility.

However, the one-day performance shows a slight dip of 0.13%, marginally underperforming the Sensex’s 0.42% gain. The one-week return of 0.80% still beats the Sensex’s 0.32%, indicating short-term momentum remains positive despite minor daily fluctuations. The 1-month return of 12.78% is particularly notable, reflecting a recent acceleration in buying interest — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Bullish Across All Key Periods

The technical picture for Sun Pharmaceutical Industries Ltd is notably robust. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across short, medium, and long-term horizons. This configuration suggests sustained buying interest and a positive momentum backdrop. The stock’s proximity to its 52-week high — just 1.54% away from Rs 1917.15 — further confirms its strength. Such a technical stance often supports continued price appreciation, although investors should remain alert to potential resistance near all-time highs.

Sector Context: Pharmaceuticals & Biotechnology Showing Broad Strength

The Pharmaceuticals & Biotechnology sector has delivered a predominantly positive set of results recently, with 12 out of 18 stocks reporting positive outcomes, four flat, and only two negative. This sector-wide strength provides a supportive environment for Sun Pharmaceutical Industries Ltd, which is among the large-cap leaders. The sector’s overall momentum may be contributing to the stock’s outperformance, but the company’s individual fundamentals and technicals remain key drivers — should investors in Sun Pharma hold, buy more, or reconsider?

Rating Context: Previously Strong Buy, Now Reassessed

MarketsMOJO had previously assigned a Strong Buy rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 18 May 2026, reflecting a reassessment of the company’s valuation, performance, and technical indicators. While the current Mojo Score stands at 78.0, the precise rating is not disclosed. The reassessment likely considers the stock’s premium valuation, consistent outperformance, and bullish moving average configuration. Such a comprehensive review ensures the rating aligns with the latest data and market conditions — what is the current rating?

Market Capitalisation and Industry Standing

With a market capitalisation of approximately ₹4,50,607.10 crore, Sun Pharmaceutical Industries Ltd is firmly established as a large-cap entity within the Pharmaceuticals & Biotechnology sector. This scale provides the company with significant resources to invest in research and development, expand its product portfolio, and navigate regulatory challenges. The stock’s valuation premium may partly reflect this market stature and the perceived stability it offers relative to smaller peers.

Short-Term Momentum vs Medium-Term Strength

While the stock’s one-month and three-month returns of 12.78% and 8.91% respectively indicate strong recent momentum, the one-day performance of -0.13% suggests minor profit-taking or consolidation. The fact that the stock has gained after two consecutive days of decline points to resilience. This pattern of short-term dips followed by recovery is typical of stocks in a sustained uptrend. The moving average alignment supports this interpretation, indicating that recent weakness may be a pause rather than a reversal — is this a recovery or a dead-cat bounce?

Long-Term Returns Highlight Enduring Value Creation

Over three and five years, Sun Pharmaceutical Industries Ltd has delivered returns of 102.80% and 172.04% respectively, far exceeding the Sensex’s 22.53% and 49.66% gains over the same periods. This long-term outperformance underscores the company’s ability to generate sustained shareholder value. Even the ten-year return of 137.11%, while trailing the Sensex’s 198.94%, remains substantial and reflects the company’s evolution through various market cycles.

Conclusion: Data Reflects a Premium Valuation Backed by Strong Performance and Technicals

The comprehensive data analysis of Sun Pharmaceutical Industries Ltd reveals a stock trading at a modest premium to its sector’s P/E ratio, supported by consistent outperformance across multiple timeframes and a bullish moving average configuration. The Pharmaceuticals & Biotechnology sector’s broadly positive results provide a favourable backdrop, while the company’s large-cap status adds to its market appeal. The recent reassessment of the rating, previously Strong Buy, reflects these factors in balance. Investors may consider the valuation premium in light of the stock’s demonstrated resilience and momentum — should investors in Sun Pharma hold, buy more, or reconsider?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today